Fig. 4

Antithrombotic treatment use by bleeding risk in eligible patients from China at Phase II and Phase III.

Bleeding risk stratification by HAS-BLED score: low (score < 3); high (score ≥ 3). AP, antiplatelet therapy; NOAC, non-VKA oral anticoagulant; VKA, vitamin K antagonist. None indicates no antithrombotic treatment